Elegir un idioma

Inicio
Nosotros
Cáncer Renal
Información
Miembros
- Ingresar
- Cuenta
- Salir

Inicio
Nosotros
Cáncer Renal
Información
Miembros
- Ingresar
- Cuenta
- Salir

julio 2020

julio 6, 2020 In Artículos

IMDC Risk Calculator

International mRCC Database Consortium

Visit IMDC Risk Calculator

Facebook
Twitter
Google+
LinkedIn

Search for:

Entradas recientes

Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
Tivozanib in renal cell carcinoma: a new approach to previously treated disease

©2019 LARCG – Todos los derechos reservados

Contacto

larcgorg@gmail.com

Seguinos

Youtube | Twitter

Asociados

IKCC Internacional Kidney Cancer Coalition
NIH National Cancer Institute
Latín American Collaborative Oncology Group

Sponsor

A. C. Camargo Cancer Center

Diseño web: /JMB

Login
Register

Remember me

Lost Your password?

You don't have permission to register